Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - other diseases
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Proceedings against Biotest AG have been closed

17.02.2017, News

Proceedings against Biotest AG have been closed Dreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the ... [More]

EUR 64.4 million operating profit in core business of B...

16.02.2017, News

EUR 64.4 million operating profit in core business of Biotest Dreieich, 16 February 2017. In line with the strategic realignment Biotest has restructured its US Therapy business. In the next ... [More]

Release according to Article 26, Section 1 of the WpHG ...

27.01.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

First patient treated in the next clinical phase III st...

25.01.2017, News

First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP) - Study no. 992 is the second pivotal phase III study ... [More]

Biotest to sell US therapy business to ADMA Biologics, ...

23.01.2017, News

Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of ... [More]

Biotest to sell US therapy business to ADMA Biologics, ...

23.01.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, ... [More]

Encouraging data of Indatuximab Ravtansine (BT-062) in ...

06.12.2016, News

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma - New data from BT-062 in combination therapy presented at 58th annual conference of ... [More]

Biotest opens new plasma collection centre in Kearney, ...

01.12.2016, News

Biotest opens new plasma collection centre in Kearney, Nebraska, USA - 13 plasma collection centres in Europe - 22 in the US to ensure long-term plasma supply Dreieich, 1 December 2016. ... [More]

Biotest supports a large international retrospective st...

23.11.2016, News

Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation - Results will provide a basis for design of a new ... [More]

Biotest increases revenues by 9%

10.11.2016, News

Biotest increases revenues by 9% - EBIT increased to EUR 26.1 million - Cash flow of EUR 46.9 million - Guidance confirmed Dreieich, 10 November 2016. In the first nine months of 2016, ... [More]

First patient treated in global clinical phase III stud...

08.11.2016, News

First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID) - Study no. 991 marks the first phase III study in the ... [More]

Altered tax assessments for 2005-2008 lead to a decreas...

04.11.2016, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG ... [More]

Biotest AG will offer recombinant factor VIII from 2017

03.11.2016, News

Biotest AG will offer recombinant factor VIII from 2017 - Cooperation with Octapharma for German-speaking markets - Fourth-generation recombinant human factor VIII preparation from a ... [More]

Interim analysis supports continuation of clinical phas...

01.11.2016, News

Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990) - Independent Data Safety Monitoring Board (DSMB) recommends to start part ... [More]

Biotest opens new plasma collection centre in Vermil...

28.09.2016, News

Biotest opens new plasma collection centre in Vermillion, South Dakota, USA - 13 plasma collection centres in Europe - 21 in the US to ensure long-term plasma supply Dreieich, 28 September ... [More]

Biotest increases EBIT significantly

11.08.2016, News

Biotest increases EBIT significantly - Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million - Increase of revenue by 6.4% to EUR 306 million - Operating Cash flow increased to EUR ... [More]

Altered Tax Assessments for 2005 - 2008

03.08.2016, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered Tax Assessments for 2005 - 2008 Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office ... [More]

Biotest AG opens fifth plasma collection centre in Hung...

29.07.2016, News

Biotest AG opens fifth plasma collection centre in Hungary - Thirteen plasma collection centres in Europe and - Twenty in the US to ensure long-term plasma supply Dreieich, 29 July 2016. ... [More]

Biotest opens new plasma collection centre in Clemson, ...

27.07.2016, News

Biotest opens new plasma collection centre in Clemson, South Carolina, USA - 12 plasma collection centres in Europe - 20 in the US to ensure long-term plasma supply Dreieich, 27 July 2016. ... [More]

Release according to Article 26, Section 1 of the WpHG ...

21.07.2016, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]